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Abstract
Background: Antimicrobial peptides derived from the natural processing of chromogranin A (CgA) are co-secreted with
catecholamines upon stimulation of chromaffin cells. Since PMNs play a central role in innate immunity, we examine
responses by PMNs following stimulation by two antimicrobial CgA-derived peptides.
Methodology/Principal Findings: PMNs were treated with different concentrations of CgA-derived peptides in presence of
several drugs. Calcium mobilization was observed by using flow cytometry and calcium imaging experiments.
Immunocytochemistry and confocal microscopy have shown the intracellular localization of the peptides. The
calmodulin-binding and iPLA2 activating properties of the peptides were shown by Surface Plasmon Resonance and
iPLA2 activity assays. Finally, a proteomic analysis of the material released after PMNs treatment with CgA-derived peptides
was performed by using HPLC and Nano-LC MS-MS. By using flow cytometry we first observed that after 15 s, in presence of
extracellular calcium, Chromofungin (CHR) or Catestatin (CAT) induce a concentration-dependent transient increase of
intracellular calcium. In contrast, in absence of extra cellular calcium the peptides are unable to induce calcium depletion
from the stores after 10 minutes exposure. Treatment with 2-APB (2-aminoethoxydiphenyl borate), a store operated
channels (SOCs) blocker, inhibits completely the calcium entry, as shown by calcium imaging. We also showed that they
activate iPLA2 as the two CaM-binding factors (W7 and CMZ) and that the two sequences can be aligned with the two CaM-
binding domains reported for iPLA2. We finally analyzed by HPLC and Nano-LC MS-MS the material released by PMNs
following stimulation by CHR and CAT. We characterized several factors important for inflammation and innate immunity.
Conclusions/Significance: For the first time, we demonstrate that CHR and CAT, penetrate into PMNs, inducing extracellular
calcium entry by a CaM-regulated iPLA2 pathway. Our study highlights the role of two CgA-derived peptides in the active
communication between neuroendocrine and immune systems.
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Introduction
Chromogranin A (CgA) is a well-studied member of the
chromogranin/secretogranin family, present in secretory cells of
the nervous, endocrine and immune systems [1]. CgA was the first
chromogranin to be characterized as an acidic protein co-stored
and co-released with the catecholamine hormones from the
chromaffin cells of the adrenal medulla. The discovery that
Pancreastatin, a CgA-derived peptide (bCGA248–293) was able to
inhibit the glucose-evoked insulin secretion from pancreatic beta-
cells [2] initiated the concept of a prohormone function for this
protein [3]. Numerous endogenous cleavage products of CgA have
since been identified in the intragranular matrix of chromaffin
cells, resulting from the proteolytic digestion at 13 sites [4] by
intragranular enzymes, such as prohormone convertases PC1/3,
PC2, neuroendocrine-specific carboxypeptidase E/H, Lys and
Arg-aminopeptidases [5]. Among the CGA derived fragments,
several induce biological activities [1] an their in vitro actions
PLoS ONE | www.plosone.org 1 February 2009 | Volume 4 | Issue 2 | e4501strongly suggest involvement in homeostatic processes, such as
calcium and glucose metabolisms [6], cardiovascular functions [7–
11], inflammatory reactions [12,13], pain relief, tissue repair [14],
gastrointestinal motility [15,16] and in the first line of defence
against invading microorganisms [17–19]. The possible implica-
tion of CgA and some of its derived-peptides in human diseases
has also been reviewed [20,21].
We have identified a range of antimicrobial peptides deriving
from the natural processing, not only of CgA but also
Chromogranin B, Proenkephalin-A and Ubiquitin co-secreted
with catecholamines upon stimulation of chromaffin cells from the
adrenal medulla [17,18,22–25]. These new antimicrobial peptides
are integrated in the concept that the adrenal medulla plays an
important role in innate immunity [26]. Furthermore, when
polymorphonuclear neutrophils (PMNs), known to accumulate at
sites of inflammation are stimulated by lipopolysaccharide or other
bacterial agents, such as Panton-Valentine leucocidin (PVL)
[27,28], these cells produce and secrete intact and processed
forms of CgA, such as Vasostatin-I and -II (residues 1–76 and 1–
113) [18] and Cateslytin (residues 344–358) [17,29–31], the N-
terminal fragment of Catestatin (residues 344–364) [32]. In view of
the established function of PMNs as central effectors cells in innate
immune responses to inflammatory stimuli, it is of a great
importance to understand the implications of the production and
secretion of CgA-derived peptides for the regulation of PMNs
responses to external stimuli.
In the present study, we have investigated the effects of two of
the potent antimicrobial CgA-derived peptides on activation of
PMNs release, i.e.: Chromofungin (CHR, bovine/human CgA47–66)
[24] and Catestatin (CAT, bovine CgA344–364) [17]. By use of
biochemical techniques, confocal microscopy, flow cytometry,
calcium imaging, surface plasmon resonance and proteomic
analyses, these two CgA peptides have now been demonstrated
to stimulate exocytosis from PMNs by provoking a transient
Ca
2+ entry independent of release from internal stores. The
mechanism by which CHR and CAT may induce Ca
2+ influx
appears to involve calmodulin (CaM) binding. The subsequent
activation of the calcium-independent phospholipase A2 (iPLA2)
in the complex regulation of store-operated channels (SOCs)
[33–37], seemingly potentiates the release of a range of PMNs
factors of importance identified by use of nanoLC-MS/MS.
Results
Since PMNs are central effectors in innate immune response to
inflammatory stimuli, we investigated the effects induced by two
highly conserved antimicrobial CgA derived peptides on these
cells. Chromofungin (CHR, RILSILRHQNLLKELQDLAL)
corresponds to the active antifungal domain CgA47–66 of bovine
and human Vasostatin-1 CgA1–76 [24] while Catestatin (CAT,
RSMRLSFRARGYGFRGPGLQL) corresponds to a potent
antimicrobial peptide CgA344–364 conserved in both cattle and
man. These two peptides are not lytic for mammalian cells and
display antimicrobial activities at the micromolar range [17,24].
CHR and CAT provoked Ca
2+ entry in PMNs
In PMNs loaded with Fluo-3, a transient Ca
2+ influx was
induced by 20 mM of either CHR or CAT (20 mM) in the
presence, but not in the absence, of 1 mM free extracellular Ca
2+
(Figure 1A). Several other CgA-derived peptides (20 mM) were
compared with CHR and CAT for influx of Ca
2+. Three
peptides derived from the N-terminal CgA domain failed to
affect the Ca
2+ influx (Figure 1A). These peptides were: CgA4–16
(NSPMNKGDTEVMK), the disulfide loop CgA17–40
(CIVEVISDTLSKPSPMPVSKEC) and the natural peptide
CgA65–76 (ALQGAKERTHQQ) previously reported to be
without antimicrobial activities [5]. Furthermore, mixtures of
peptides resulting from the tryptic digest of CHR (R, ILSILR,
HQNLLK, ELQDLAL) and CAT (SSMK, LSFR, ARAYGFR,
GPGPQL) were without effect on Ca
2+ influx
, nor was scrambled
CAT peptide (SLPRRQLPSSAGMRGGKFAYF) of any effect
(Figure 1A). Hence, the complete sequences of CHR and CAT
appear to be essential for the induction of the transient Ca
2+
influx.
The inducing effects of CHR and CAT on the Ca
2+ influx were
concentration-dependent in the 5–200 mM range (Figure 1B, C).
Interestingly, the simultaneous addition of CHR and CAT at
equal concentrations provoked a higher Ca
2+ increase (Figure 1C)
than the sum of effects observed by separately added peptides
(Figure 1B and C), suggesting that CHR and CAT may have
synergic effects on the transient Ca
2+ entry in PMNs.
An immediate increase of activated PMNs (M1/M2) was
observed 15 s after the application of either CHR or CAT
(Figure 2A). With different concentrations of CHR or CAT (0–
200 mM), the percentage of activated PMNs was concentration
dependent, being maximal at 50 mM for CHR (45%) and CAT
(60%), respectively (Figure 2B).
Ca
2+ entry evoked by CHR and CAT via Ca
2+ selective
Store Operated Calcium channels (SOCs)
Pretreatment of PMNs with the specific blocker of SOCs, 2-
aminoethyl diphenylborinate (2-APB) for 2 min before addition of
peptides, completely blocked the entry of extracellular Ca
2+ by
CHR or CAT (Figure 3A and 3B), suggesting that the two peptides
were involved in the activation of Store Operated Calcium Entry
(SOCE) through SOCs. Ca
2+ entry in response to CHR and CAT
was also compared to that induced by Arachidonic Acid (AA),
acting through the Arachidonic-Regulated Channels (ARCs)
(Fig 3C). The calcium influx induced by 50 mM AA was insensitive
to 2-APB, while inhibited by gadolinium chloride (Gd
3+), in
marked contrast to the influx induced by CHR or CAT
(Figure 3A–C). Thus, the Ca
2+- entry induced by the two CgA-
derived peptides was pharmacologically distinct from that by AA.
Finally, the specificity for divalent cation entry into PMNs
loaded with Fura-2 was assessed by comparison of the peptide
induced Ca
2+ entry (traces a and b) with that of Mn
2+ (traces c and
d) at the corresponding wavelengths of excitation (lex340nm and
lex360nm) (Figure 4). By comparison of the traces for CAT (a, c)
and CHR (b,d) there was no evidence for Mn
2+ entry in response
to either peptide, consistent with activation of SOCs selective for
Ca
2+ and non-permeable for Mn
2+ in PMNs [38].
Calmodulin binding of CHR and CAT
The uptake of rhodamine-labeled CHR and CAT into isolated
PMNs was demonstrated by confocal microscopy (Figure 5A).
After 2 min incubation, the fluorescent rhodamine-labeled
peptides were detected in the cytoplasm. In contrast, the control
peptide, rhodamine-labeled Hippocampal Cholinergic Neurosti-
mulating Peptide (HCNP), unable to induce Ca
2+ influx into
PMNs (not shown), was not detected in the cytoplasm, indicating a
specificity for the entry of rhodamine-labeled CHR and CAT
(Figure 5A).
The two cationic sequences CAT and CHR may be aligned
with two Ca
2+- dependent CaM binding motifs 1-8-14 B and 1-5-
10 [39], as illustrated in Figure 5 B and previously demonstrated
for binding of CHR to CaM [24,40]. Interactions between CaM,
CAT and CHR were assessed by surface plasmon resonance (SPR)
(Figure 5 C1), revealing that not only CHR but also CAT
Ca2+ Entry in PMNs
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inactive. In addition, CaM interacts with both CHR and CAT
(Figure 5C2) when assayed by CaM-binding affinity chromatog-
raphy and dot blot immunodetection of CgA in the fixed material
with anti-CHR (monoclonal anti-CGA47–66) [14] and anti-CAT
(polyclonal anti-CGA344–364) [17].
Role of iPLA2 in the Ca
2+ entry evoked by CHR and CAT
Previous studies have demonstrated that functional iPLA2 is
involved in activation of SOCs from different cell types [37] and
that displacement of inhibitory CaM from iPLA2 may activate
iPLA2, subsequently generating of lysophospholipids for activation
of SOCs [36]. Confocal microscopy confirmed the presence of
immunoreactive iPLA2 in PMNs (Figure 6A, right panel). The
membrane localization of immunoreactive iPLA2 could be verified
after subcellular fractionation, Triton X-100 treatment and
western blotting (Figure 6B, [36]). The enzymatic activity of
iPLA2 in PMNs was stimulated not only by two CaM inhibitors,
i.e. calmidazolium (CMZ) and N-(6-aminohexyl)-5-chloro-l-
naphthalenesulfonamide (W7), but also by CHR and CAT
(Figure 6C). Interestingly, a comparison of CHR and CAT
sequences with two CaM-binding peptides of iPLA2 reveals
marked homologies (Figure 6D). Of note, the CHR sequence
may be aligned with one of the iPLA2 CaM-binding motif
(iPLA2618–635), while the CAT sequence aligns with another, i.e.
the iPLA2 CaM-binding motif (iPLA2691–709) [41].
CHR and CAT directly activate SOCs via iPLA2
Two inhibitors of iPLA2 were compared with 2-APB for effects
on peptide inducing Ca
2+ influx (Figure 6C, 7A, B). Bromoenol
lactone (BEL), a specific inhibitor of iPLA2 and bromophenacyl
bromide (BPB), an inhibitor of PLA2, abolished the transient Ca
2+
influx induced by CHR or CAT similarly to 2-APB. In addition,
the two CaM antagonists W7 and CMZ induced longer lasting
rises in influx (Figure 7C, D), that were significantly suppressed by
the PLA2 inhibitors BEL and BPB and the specific SOC blocker 2-
APB.
Interestingly, CMZ and some CaM inhibitory peptides may
directly activate SOCs without the release of intracellular Ca
2+
stores [42–44]. Hence, these findings indicate that CAT and
CHR, being unable to evoke a Ca
2+ mobilization from
intracellular stores in absence of extracellular Ca
2+, by their 2-
APB sensitive induction of Ca
2+ entry via SOCs may converge on
iPLA2 in a manner similar to the two CaM inhibitors W7 and
CMZ.
Proteomic analysis of the PMNs secretions released by
CHR and CAT
PMNs secretions obtained after treatment with CHR and CAT
were chromatographied by HPLC (Figure 8A, B) and the isolated
fractions were identified by NanoLC-MS/MS analysis (supple-
mentary data). Factors involved in innate immunity were identified
among these proteins, i.e. lactotransferrin, lysozyme, neutrophil
gelatinase associated lipocalin, S100 calcium binding protein A8,
S100 calcium binding protein A9, heat shock 70 kDa protein and
leukotriene A4 hydrolase (Figure 8C and complete data in the
annexe with Figures S1 and S2).
CgA-derived fragments in the PMN secretions obtained after
treatment with CHR and CAT were detected by western blotting,
revealing traces of Vasostatin-1 and a CAT-including fragment
(CgA340–395) (data not shown), consistent with the previously
report of several CAT-including peptides with molecular weights
in the range 70-15 kDa [17]. The major fragment corresponds to
CgA340–395 (15–17 kDa) after stimulation of PMNs by CAT.
Discussion
The present experiments are the first to demonstrate that not
only CAT but also the distinctly different sequence CHR may play
Figure 2. Concentration-dependent Ca
2+-influx after stimula-
tion of human PMNs by CHR and CAT. A) Representative diagrams
of flow cytometry determination of the Ca
2+ influx in the basic (M1) and
peptide-activated (M2) windows, respectively. These influxes (in black)
were obtained 15 s after the addition of 50 mM CHR or 50 mM CAT at
t=0 (in grey). PMNs activated by peptide-induced Ca
2+ influx
correspond to the M2 population. B) Flow cytometry quantification
of PMNs in the M2 window in percent of the total initial population of
PMNs, after 15 s exposure to increasing concentrations of CHR or CAT
(1–200 mM).
doi:10.1371/journal.pone.0004501.g002
Figure 1. Ca
2+ influx evoked in human PMNs by CGA-derived peptides. For flow cytometry analysis, human PMNs (5.10
5 cells/ml) were
loaded with Fluo-3AM probe (5 mM) and its fluorescence intensity of Fluo-3 was monitored at lEm530 nm. Traces were obtained from 3000 PMNs and
are averaged from triplicates at least. Peptides were added in the Ca
2+-free EGTA buffer at t=0 and 1.1 mM CaCl2 at t=620 s. A) Time course
variations of the intracellular Ca
2+ in human PMNs in response to 20 mM CAT or 20 mM CHR and compared with other CgA-derived peptides (20 mM
of CgA4–16, CgA17–40 or CgA65–76), tryptic digests of either 20 mM CAT, CHR or scrambled CAT. B, C) Time course variations of the intracellular Ca
2+ in
human PMNs in response to increasing concentrations (1–200 mM) of CHR (B), CAT (C) or a mixture of 50 mM CAT and 50 mM CHR (C).
doi:10.1371/journal.pone.0004501.g001
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2+ signaling outside the chromaffin cells, i.e. serving as
immunomodulators for activation of PMNs secretion.
A rapid and effective response to challenge with pathogens is
essential for the survival of all living organisms. Natural cationic
host defense peptides represent lead molecules that boost innate
immune responses and selectively modulate pathogen-induced
inflammatory responses [45]. Among the different mechanisms
that have evolved to this effect, the production of a large variety of
natural antimicrobial peptides has gained increasing attention.
CHR and CAT are two antimicrobial peptides derived from
CgA. They are stored in secretory granules of chromaffin cells and
PMNs in a larger form, which may be processed extracellularly to
the mature active peptides [17,18]. In the intragranular matrix,
they result to the processing of CgA by numerous enzymes such as
prohormone convertases (PC1 and 2), aminopeptidases and
carboxypeptidases. In the extracellular medium, larger forms may
beprocessedbykallikreinlocatedattheplasmicmembraneleveland
bycirculatoryproteolyticenzymessuchasplasminandthrombin[1].
In addition, some bacterial virulence factors are indeed proteolytic
enzymes, i.e. Glu-C protease from Staphylococcus aureus, and might
continue the natural processing of CgA to generate the CHR and
CAT fragments during infections [17,18,46].
To date only CAT has been reported to act via a classical
surface receptor, i.e. the nicotinic acetylcholine receptor [32]. On
the other hand, several 70–80 kDa membrane binding proteins
have been reported for Vasostatin-I (CgA1–76) [47,48]. Further-
more, the sequences of CHR and CAT may also be aligned with
the cell penetrating peptide (CPP), Penetratin, i.e. (Figure 9 insert),
pointing the possibility for CHR and CAT, as new members of the
family of CPPs [49].
Figure 3. Ca
2+ influx in PMNs induced by CHR, and CAT and arachidonic acid (AA). Time-lapse intracellular calcium imaging was performed
on cells loaded with 1 mM Fura-2-AM and then further treated with 20 mM CHR, 20 mM CAT and 50 mM (AA) in Hepes-buffered Krebs medium in
presence of 2.5 mM CaCl2. A–C) Left panels, Representative traces showing average change in [Ca
2+]i (F340nm/F380nm) recorded in the ratio mode
from individual PMNs loaded with Fura-2. The arrow indicates the time of addition of 20 mM CHR, 20 mM CAT and 50 mM AA. In separate assays (as
indicated) either 100 mM 2-aminoethyl diphenylborinate (2-APB) or 1 mM gadolinium chloride (Gd
3+) were applied 2 min before addition of peptides
or AA. Traces are averaged from triplicates. Right panels, Summary of data in left panels, showing the maximal Ca
2+ influx (mean ratio6S.E.)
obtained with the different conditions as indicated below bars. (n), number of PMNs used for each experiment; *, indicate significant differences
(p,0.05), significance for difference from effect of CHR, CAT or AA alone.
doi:10.1371/journal.pone.0004501.g003
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cellular signal transduction pathways, regulating crucial functions
such as secretion, cell motility, proliferation and cell death.
Increased in intracellular Ca
2+ derives mainly from two sources:
internal stores releasing Ca
2+ into the cytosol and channels in the
plasma membrane that open to allow external Ca
2+ to flow into
the cell. In PMNs, calcium signaling has been reported to be
involved in oxidase activation, cell degranulation and priming
response to a wide variety of proinflammatory molecules [35]. The
present experiments have demonstrated that the two CgA
peptides, CHR and CAT, penetrate rapidly into PMNs
(Figure 5A) and subsequently interact with CaM (Figure 5C) to
activate iPLA2 (Figure 6C). Displacement of CaM leads to iPLA2
activation and production of lysophospholipids inducing the
opening of SOCs [36], the entry of Ca
2+ and the release of innate
immune factors among a long list of proteins (Figure 8C and
Figures S1 and S2).
The SOCE pathway remains one of the most intriguing and
long lasting mysteries of Ca
2+ signaling [43]. The main question
concerns the origin of the signal [43,50]: how does depletion of the
internal Ca
2+ store activate Ca
2+ entry through the SOC in the
plasma membrane?. The Calcium Influx Factor (CIF) is a specific
factor produced by the cells following depletion of Ca
2+ stores [51]
and corresponds to the diffusible messenger that is produced by
Ca
2+ stores upon their depletion traveling to the plasma
membrane to activate SOCs and Ca
2+ entry [43]. The mechanism
by CIF may activate SOCs with a displacement of CaM from the
inactive complex with iPLA2. The subsequent formation of
lysophospholipids and the opening of SOCs, consistent with an
activation of SOCs by displacement of inhibitory CAM from the
inactive complex with iPLA2 [36,37,43]. Thus, CaM inhibitors
such as chemical substances and peptides, may activate SOCs by
interfering with the CaM-iPLA2 complex [36,43]. The present
experiments have made evident that CHR and CAT induce a 2-
APB sensitive Ca
2+ entry without depletion of Ca
2+ stores in a
similar manner to CaM inhibitors, pointing to iPLA2, as the most
likely target for these two peptides, once penetrated into the
cytoplasm.
Of note, CAT is an inhibitory peptide controlling catechol-
amine release from chromaffin cells and noradrenergic neurons by
an autocrine regulatory mechanism, non-competitively blocking
the influx of Ca
2+ coupled to activation of the nicotinic
acetylcholine receptor, as illustrated in Figure 9, but not when
triggered by membrane depolarization [32].
Several proteins involved in innate immunity (lactotransferrin,
heat shock 70 kDa protein, lysosyme, neutrophil gelatinase
associated lipocalin, protein S100-A8, protein S100-A9 and
leukotriene A-4 hydrolase were identified by using proteomic
analysis in the secretions of neutrophils stimulated by CHR and
CAT (Figure 8C). In neutrophils, azurophil, specific and gelatinase
granules contain host defense proteins in their luminal spaces. The
extent of mobilization of the three types of granules depends on
the stimulus intensity: gelatinase granules are most easily mobilized
followed by specific granules and then azurophil granules.
Lactotransferrin is an iron-binding protein that is released from
activated neutrophils at sites of inflammation by the three types of
granules [52] and has antimicrobial, as well as anti-inflammatory
properties [53]. Lactotransferrin serves as an autoregulator to
retain PMNs at inflammatory sites [54] and it was able to delay
spontaneous apoptosis of neutrophils [55]. The anti-inflammatory
activity of lactotransferrin is due to binding and neutralization of
proinflammatory molecules and its capacity to promote activation
of neutrophils and macrophages [56]. Lysozyme is also released by
three types of granules [52]. In addition to enzymatic lysis of
bacterial cell wall, it can also kill bacteria by a non-enzymatic
mechanisms [57]. Neutrophil gelatinase associated lipocalin
(NGAL) was found in specific granules of neutrophils [58,59]. It
is involved in the allosteric activation of matrix-metalloproteinase
(MMP)-9 and protection from degradation. It may function as an
effector molecule of innate immune system [58,60].
Proteins S100-A8 and A9, two Ca
2+-binding proteins of the
S100 family are secreted from neutrophils by the three types of
granules as a heterodimeric complex (S100-A8/S100-A9) [61–63].
High levels of the proteins have been found in the extra-cellular
milieu during inflammatory conditions [64,65]. The S100-A8/A9
heterodimer is an antimicrobial complex that exhibits cytokine-like
functions in the inflammatory sites via activation of NFkappa B
and p38MAPK [66]. Hsp70, an ubiquitous family of protein
chaperones that assist in folding of newly synthesized peptides and
translocation of proteins across biological membranes, plays
regulatory roles in signal transduction, cell cycle and apoptosis
[67]. Hsp70 is known to contribute to the mechanisms of cell
protection against a variety of stress and cytotoxic factors,
providing an increase of cell survival [68]. Leukotriene A-4
hydrolase is released by the specific granules of neutrophils. It
catalyzes the final and commited step in the biosynthesis of
leukotriene B4, a potent chemotactic agent for neutrophils,
eosinophils, monocyted and T cells that play key roles in the
innate immune response [69].
A considerable number of studies have demonstrated that the
neuroendocrine and immune systems communicate to promote
reciprocal regulation in the host. Not only may immune cells sense
pathogens and secrete proteins that modify cells of the neuroen-
docrine system but factors secreted by the neuroendocrine system
may also bring about changes in immune cell activity [26].
In addition to CAT, substance P is another neuro-immuno-
modulator that may inhibit nicotinic cholinergic-stimulated
catecholamine release, but displays a lower potency [70]. PACAP
displays numerous functions in cells of neuronal and non
neuronal origin and functional VIP/PACAP receptors have been
Figure 4. Specificity of the Ca
2+ entry provoked by 50 mM CHR
and 20 mM CAT. Characterization by spectrofluorimetry of the
specificity of the Ca
2+ entry induced by 50 mM CHR or 20 mM CAT for
comparison with peptide effects on Mn
2+ entry. Simultaneous
recordings of fluorescent intensity variations of PMNs loaded with
Fura-2 in the presence of 1 mM CaCl2 (a, b) and 0.2 mM MnCl2 (c, d) at
the corresponding wavelengths of excitation lEx340 nm and lEx360 nm.
Divalent cations and peptides were added as indicated by arrows.
Recordings are representative of three experiments.
doi:10.1371/journal.pone.0004501.g004
Ca2+ Entry in PMNs
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2+- dependent pro-inflam-
matory activities through the activation of multiple regulatory
pathways [71]. Thus, it was demonstrated that the extracellular
and intracellular Ca
2+ play key roles in PACAP mediated
proinflammatory activities [72]. In addition, it has been reported
that, in contrast to the inhibitory effect of CAT, PACAP may
induce an increase of Ca
2+ entry and catecholamine release in
bovine chromaffin cells by a a unique pathway distinct from
nAChR, VOCs and SOCs [73]. Hence, in contrast to the action of
PACAP, CAT may control the proinflammatory activity via a
Figure 5. Interaction of CHR and CAT with calmodulin (CaM). A) Fluorescence confocal microscopy of PMNs after incubation during
120 s with 20 mM rhodamine-labeled peptides (Rho-CHR or Rho-CAT). Control peptide: 20 mM rhodamine labeled Hippocampal Cholinergic
Neurostimulating Peptide (Rho-HCNP). The PMNs nuclei were labeled with Draq-5. B) Alignment of the CHR and CAT sequences with two CaM
binding motifs 1-8-14 B and 1-5-10. The alignment has been obtained manually so that hydrophobic residues occupy invariant positions shown
with boldface letters. The net positive charge is also indicated. C) (1) Interactions between CaM, CAT and CHR by Surface Plasmon
Resonance (SPR) Peptides were immobilized on a CM5 Biacore chip using amine-coupling chemistry. CaM (5 mM) was added at arrow and allowed
to stabilize for 10 min. Dissociation by washing was recorded for the following 10 min. All measurements were performed at 20uC. The resulting
sensorgrams were analyzed using BIAevaluation Software. (2) Calmodulin-Affinity Chromatography of CHR and CAT. The retained and eluted
peptides were immunodetected by dot blot with anti-CHR (monoclonal anti-CgA47–68) and anti-CAT (polyclonal anti-CgA344–364). Wash (5
th wash after
adsorption of peptides).
doi:10.1371/journal.pone.0004501.g005
Ca2+ Entry in PMNs
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mechanism while enhancing PMNs secretions of a range of
immunoactive factors.
To conclude, the data reported here are important for our
understanding of the role for CgA in innate immunity and for its
crucial role as a mediator in the cross-talk between the
neuroendocrine and immune systems. All together, the immuno-
modulatory activities of CHR and CAT may be important for the
design of pharmacological strategies to maintain homeostasis
during recruitment of PMNs in microbial and systemic infections.
Materials and Methods
Peptide synthesis
All the synthetic peptides were prepared on an Applied
Biosystems 433A peptide synthesizer (Foster City, USA), using
the stepwise solid-phase approach with 9-fluorenylmethoxycarbo-
nyl (Fmoc) chemistry. Then, the synthetic peptides were purified
by RP-HPLC on a Macherey Nagel Nucleosil RP 300-7C18
column (106250 mm; particle size 7 mm and pore size 100 nm).
Rhodamine fluorophore 5(6)-carboxytetramethyl rhodamine was
conjugated with peptides at the N-terminal extremity, as
previously described [24]. Synthetic peptides were analysed by
mass spectrometry and automated Edman sequencing on an
Applied Sequencing System (Applied Biosystems, Foster City,
USA) [5]. MALDI mass measurements were carried out on an
Ultraflex
TM TOF/TOF (Bruker Daltonics, USA) to perform a
rapid control of synthetic peptides according to the procedure
previously reported [74].
Cells and flow cytometry measurements
Human PMNs were prepared from buffy coats purchased at the
Etablissement Franc ¸ais du Sang – Strasbourg, France from
anonymous and healthy donors from either sex. Briefly, 40 mL
of a 1/3 (vol/vol) dilution of blood cells in 0.9% (wt/vol) NaCl was
layered on 12 mL of 15 J Prep (Techgen International, Voisins le
Bretonneux, France). After centrifugation at 8006 g for 20 min,
the pellet was suspended in 30 mL of 0.9% NaCl, added to 10 mL
of 6% (wt/vol) dextran, and sedimented for 30 min. Thirty mL of
the supernatant was centrifuged for 10 min at 8006g. The pellet
was suspended in Hepes buffer (140 mM NaCl, 5 mM KCl,
10 mM glucose, 0.1 mM EGTA, 10 mM Hepes, 3 mM Tris;
pH 7.3) and the contaminating erythrocytes were removed by
hypotonic lysis for 45 s and subsequent washing in Hepes buffer
[75]. The final suspension was adjusted to a concentration of 6.10
6
PMNs/mL and 0.1% (Wt/vol) bovine serum albumin was added
to prevent non-specific leucotoxin adherence on tube walls.
To flow cytometry measurements PMNs were suspended at a
concentration of 5.10
5 cells/mL in Hepes and measurements from
3000 PMNs were carried out using a FacSortH flow cytometer
(Becton-Dickinson, Le Pont de Claix, France) equipped with a
15 mW argon laser tuned to 488 nm [76].
We evaluated the intracellular calcium, using flow cytometry of
cells previously loaded with 5 mM Fluo-3 (Molecular Probes, New
Brunswick, USA). The increase of Fluo-3 fluorescence was
measured with different CgA-derived peptides in absence or after
addition of 1.1 mM extracellular CaCl2 [77]. Fluo-3 fluorescence
was measured from the fluorescence light 1 (FL1: lEm=530 nm)
using Cell Quest Pro
TM software (Becton-Dickinson, Le Pont de
Figure 6. CHR and CAT stimulate iPLA2 activity. A) Fluorescence confocal microscopy of PMNs: Left, PMNs treated only with the
secondary antibody (Alexa Fluo 488-conjugated donkey anti-rabbit IgG dilution 1:2000). Right, PMNs stained with polyclonal anti-iPLA2 as primary
antibody before Alexa Fluo 488 conjugated donkey anti-rabbit IgG. B) Western-blot analysis: The presence of a 82 kDa protein corresponding to
iPLA2 was immunodetected in the membrane fraction obtained from PMNs. A comparable signal was obtained from the supernatant fraction of
membranes treated with 0.1% Triton X-100. C) iPLA2 activity assay: Stimulation of iPLA2 activity after treatment by 20 mM CHR or 20 mM CAT for
30 min at 37uC and comparison with the effects of two CaM-binding factors (1 mM CMZ, 50 mM W7) and one iPLA2 inhibitor (25 mM BEL). Activity of
iPLA2 is expressed as the absorbance (Abs/mg of protein) at l405 nm. Results from two similar experiments, each performed in triplicate are presented
as mean6S.E. * p,0.05, significance for difference from controls. D) Alignment of CHR and CAT sequences with two CaM-binding peptides
of iPLA2. CHR sequence has been aligned with the iPLA2 CaM-binding motif aa 618 to aa 635 while the CAT sequence has been aligned with the
iPLA2 CaM-binding motif (691–709). Corresponding homologous residues are in bold and underlined fonts.
doi:10.1371/journal.pone.0004501.g006
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2+ entry evoked by CHR and CAT in PMNs. A–D) Left panels: Effects of the SOC blocker (100 mM2 -
APB) and inhibitors of iPLA2 (25 mM BEL) and PLA2 (10 mM BPB) on Ca
2+ entry evoked by 20 mM of CHR or CAT, and two CaM antagonists (30 mMW 7
and 1 mM CMZ). The representative traces show the average change in intracellular Ca
2+ concentration (Fura-2 ratio, F340/F380) recorded
simultaneously in a number of individual PMNs at 37uC. The following inhibitors were added: BEL (30 min), BPB (10 min) and 100 mM 2-APB (2 min)
before addition of peptides or CaM antagonists (at arrows). Results are obtained from at least three independent experiments. Right panels: Bars
represent the maximum Ca
2+ influx (Ratio6S.E.) in different treatments (indicated below each bar); (n) number of PMNs; * p,0.05, significance for
difference from peptide or CaM antagonist alone.
doi:10.1371/journal.pone.0004501.g007
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independent experiments of different cell preparations. Mean
variations, mainly never exceed 10% of the measured values.
Time-lapse intracellular Ca
2+ imaging
PMNs were incubated for 30 min at 37uC in Hepes-buffered
Krebs medium (130 mM NaCl, 4.5 mM KCl, 1.2 mM MgSO4,
2.5 mM CaCl2, 11 mM D-glucose, 10 mM Hepes, pH 7.4) with
2 mM Fura-2-AM. Cells were then washed with Hepes-buffered
Krebs medium and subsequently incubated for 20 min to allow
Fura-2-AM hydrolysis. After three additional washes the cells were
placed on an inverted microscope (Axiovert 35M Zeiss, Germany),
superfused with Krebs solution (1 mL/min), and alternatively
illuminated at 350610 nm and 380610 nm. The fluorescent
emission was observed using a long pass filter at 510 nm. For each
excitation wavelength and every 2 s an image pair was recorded
using a CCD camera (ImageEM
TM, Hamamatsu Photonics,
Hamamatsu, Japan) and fluorescence ratio images were calculated
subsequently using Metafluor
TM software (Molecular Devices,
Downingtown, USA).
Spectrofluorometry determination
PMNs were loaded with Fura-2 as above and washed in EGTA
buffer with 1.1 mM CaCl2 added. Continuous variations of
fluorescence intensities were recorded using a dual excitation and
dual emission spectrofluorometer Deltascan (Bioritek, PTI,
Chamarande, France) with slits set at 4 nm. One mL of PMNs
(4.10
6 cells/mL) was added to 1 mL of the assay solution under
constant stirring in a 4 ml cuve (1 cm light path) thermostated at
37uC. Wavelengths were settled at 340 nm (Ca
2+) and 360 nm
(Mn
2+) for excitation, and 510 nm for emission. Data were
expressed in arbitrary units.
Confocal microscopy analysis of rhodamine-labelled
peptide loaded PMNs
PMNs (1.10
6/mL) were incubated 2 min at room temperature
(RT) with rhodamine-labelled peptides (20 mM) in Phosphate
Buffered Saline consisting of 10.5 mM KH2PO4, 30 mM
Na2HPO4, 0.154 M NaCl, pH 7.4, washed and subsequently
centrifuged by cytospins of 1–2.10
5 isolated PMNs onto glass
slides (300 rpm, 10 min, RT). Cytospins were fixed with 4% (v/
v) paraformaldehyde in PBS at RT for 20 min, then incubated
with Draq-5 (dilution1:500, Biostatus Limited., Leicestershire,
UK) for 15 min. Stained cells were monitored with a Zeiss LSM
510 laser scanning microscope (Zeiss, Iena, Germany) equipped
with a Planapo oil immersion objective (663, numerical aperture
1.4).
Figure 8. HPLC of proteins in PMNs secretions induced by CHR and CAT and implication for innate immunity. A, B) Secretion from
PMNs (1.10
8 cells) was induced during 30 min stimulation by (A) 20 mM CHR or (B) 20 mM CAT. The secreted proteins .3 kDa were purified by RP-
HPLC on a Macherey Nagel reverse-phase C18 column (46250 mm; particle size 5 mM and pore size 100 nm). Numbered peaks in the chromatograms
indicate protein fractions subjected to proteomic analyses. (C) Proteomic identification by NanoLC-MS/MS analysis of protein fractions involved in
innate immunity (protein identification probability .93%). The numbered HPLC fractions correspond to the peaks of secreted protein in the
chromatograms presented in A and B, respectively.
doi:10.1371/journal.pone.0004501.g008
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Experiments were conducted on a Biacore 3000
TM (GE
Healthcare) and peptides were immobilized on a CM5 Biacore
chip using amine-coupling [78]. The surface of the chip was
activated for 7 min at a flow rate of 5 mL/min with a mixture of
50 mM NHS and 0.2 mM EDC. Peptides were covalently linked
tothesurfacegivingupto2000resonanceunits(RU).Ethanolamine
(1M,pH8.5)was injectedfor 7 min to block the remaining activated
groups. 5 mM CaM (Sigma, St. Louis, MO, USA) addition was
performedataninjectionflowof20 mL/minin50 mMNaCl,2 mM
CaCl2, 20 mM Tris pH6.5 until stabilization was reached (10 min).
Dissociationwas registeredfor10 min aftertheend ofinjections. All
measurementswereperformedat20uC.Sensorgramswereanalyzed
by using BIAevaluation Software.
Calmodulin-Affinity Chromatography and dotblot
immunodetection
CHR and CAT were prepared in buffer A (50 mM NaCl,
2 mM CaCl2, 50 mM Tris-HCl, pH 7.5) and loaded on 0.1 ml
CaM-Sepharose 4B column (GE healthcare, Buckinghamshire,
United Kingdom) with molar ratio 10:1. The mixtures were
incubated at room temperature for 1 h. Afterwards, the column
was washed (x5) with 1 mL of buffer A, and (x3) 0.1mL buffer B
(50 mM NaCl and 2 mM EGTA, 50 mM Tris-HCl, pH 7.5) were
used to elute the CaM binding peptides. The elutions were
analyzed by dotblot onto PVDF membrane with pore 0.2 mM
(Millepore, Billerica, MA, USA) with specific antibodies anti-CHR
(monoclonal anti-CGA47–68 (dilution 1:5,000) and anti-CAT (anti-
CGA344–364 (dilution 1:20,000) [17,24]. Immunoreactivity signals
Figure 9. Model for the action of CHR and CAT on PMNs activation. Stress and infection lead to two different pathways for stimulation of
PMN secretion, by release of CgA and CgA-derived peptides from the adrenal medulla, as indicated by 1a–6a (black), and by PVL leucocidin
stimulation by S. aureus infections, as indicated by 1b–3b (grey), respectively. Abbreviated symbols: P (CHR, CAT), P’ (CAT), CPP (Cell Penetrating
Peptide), CaM (calmodulin), iPLA2 (calcium independent phospholipase A2) LysoPL (lysophospholipids); GC (Golgi complex); PVL (Panton-Valentine
leucocidin), R (receptor). The stress-stimulated pathway leads to penetration of P into the cytoplasm (2a), resulting in removal of inhibitory CaM,
activation of iPLA2 to produce LysoPL (3a) and activation of Ca
2+ influx through SOC (4a), converging on activated docking of secretory granules (5a)
and subsequent release of proteins of relevance for innate immunity (6a). The negative feedback induced by P’ on nicotinic cholinergic receptor of
chromaffin cell is also indicated (7a). The infective route leads to activation of the putative PVL receptor coupled to opening of Ca
2+-channels and a
rise in intracellular Ca
2+ (3b) that converges on docking of secretory granules and subsequent secretion of proteins of relevance for innate immunity
(6a). Transcription of CgA in response to stress and infection is also indicated. Insert.The alignment of the two P sequences (CHR and CAT) with that
of Penetratin (Cell penetrating peptide, CPP).
doi:10.1371/journal.pone.0004501.g009
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peroxidase (dilution 1:400,000, Jackson Immunoresearch labora-
tories, Baltimore Pike, USA).
Immunocytochemistry of iPLA2 in PMNs
Cytospins were prepared by centrifugation of 1–2.10
5 isolated
PMNs onto glass slides (300 rpm, 10 min), then fixed with 4% (v/
v) paraformaldehyde in PBS, at RT for 20 min, permeabilized
with PBS containing 1% (v/v) Triton X-100 (Sigma, St. Louis,
USA) at RT for 30 min, and blocked by incubation in PBS
containing 0.25% (w/v) bovine serum albumin. Subsequently,
cytospins were incubated with primary antibodies anti-iPLA2
polyclonal antibody (dilution 1:100, Cayman chemical, Ann
Arbor, USA) for 1 h at 37uC. Cytospins were washed with PBS,
then incubated with secondary antibodies Alexa 488-conjugated
donkey anti-rabbit IgG (dilution 1:2000, Molecular Probes,
Carlsbad, USA) during 45 min at 37uC, finally incubated with
Draq-5 (dilution 1:500) for 15 min. Immunofluorescence staining
was monitored with a Zeiss LSM 510 laser scanning microscope
equipped with a Planapo oil immersion objective (663, numerical
aperture 1.4).
Detection of iPLA2 in PMNs and iPLA2 activity assay
Subcellular fractionation of PMNs. PMNs (5.10
7/mL)
were sonicated (10 W) in the absence or presence of 1% (v/v)
Triton X-100, in the buffer 1 mM phenylmethysulphonyl fluoride,
1 mM EDTA, 50 mM Tris-HCl pH 7.5 for 3 times of 10 s with
15 s break between cycles, then spun down at 10,0006 g for
15 min at 4uC. The pellet containing membranes was collected
and the supernatant was further centrifuged at 100,0006 g for
60 min at 4uC [44]. The amount of proteins contained in
membrane and cytoplasm fractions was determined by Bradford
method, and both preparations were stored at 220uC for later use.
Gel electrophoresis and Western-blot analysis of iPLA2 in
PMNs. Fifty mg proteins of each sample were separated on 12%
sodium dodecyl sulfate-polyacrylamide gel electrophoresis SDS-
PAGE gradient gels (SDS-PAGE) and electrotransferred onto
polyvinyldifluorene membranes (GE Healthcare Bioscience). IPLA2
were detected with a polyclonal anti-iPLA2 (dilution1:500, Cayman
Chemicals, Ann Arbor, MI, USA), and signal was developed using
goat anti-rabbit IgG conjugated to peroxidase (dilution 1:50,000,
Jackson Immunoresearch Laboratories, Baltimore Pike, USA) to
determine immunoreactivity [79].
iPLA2 activity assay. PMNs (3.10
8) were collected, sonicated
3 times for 10 s with a 15 s break between cycles, and centrifuged
at 15,0006 g for 20 min at 4uC. The supernatant was removed
and kept on ice. After determination of the protein concentration
(Bradford assay), iPLA2 activity measurement was obtained in
presence of different peptide concentrations using the cPLA2 assay
kit, according to the modified method previously reported (cPLA2
assay kit, Caymen chemical), [36]. Results were from two similar
experiments, each performed in triplicates.
Characterization of secretions obtained after stimulation
of PMNs by CHR and CAT
Stimulation and purification. PMNs secretory products
were obtained after stimulation of 1.10
8 PMNs with 20 mM CHR
or 20 mM CAT in EGTA buffer for 20 min. PMNs were
centrifuged at 8006 g for 10 min at 4uC and the supernatant
was recovered. Desalting and elimination of low molecular weights
protein were achieved by centrifugation with a molecular cut-off
3 kDa Centricon (Pall, New York, USA), then the material was
stored at 220uC for further analyses.
PMNs secretions induced by CHR and CAT were purified
using a DIONEX Dual Gradient system (Dionex, Sunnyvale,
USA) and a Nucleosil RP300–5C18 column (46250 mm, 5 mm
particle size, 300-A ˚ porosity; Macherey-Nagel, Hoerdt, France).
Absorbance was monitored at 214 nm, and the solvent system
consisted of 0.1% (v/v) trifluoroacetic acid in water (solvent A) and
0.1% (v/v) trifluoroacetic acid in 70% (v/v) acetonitrile-water
(solvent B with a flow rate of 1 mL/min. Gradient was indicated
on chromatograms and fractions of 700 mL were collected.
Mass spectrometry analysis. The cysteine residues from
the RP-HPLC fractions were reduced by 50 mLo f1 0 m M
dithiothreitol at 57uC and alkylated by 50 mLof 55 mM
iodoacetamide. The proteins were digested with 40 mLo f
12.5 ng/mL of modified porcine trypsin (Promega, Madison, WI,
USA) in 25 mM NH4HCO3 at 37uC for 14 h.
The generated peptides were analyzed directly by NanoLC-
MS/MS on an Agilent 1100 Series HPLC-Chip/MS system
(Agilent Technologies, Palo Alto, USA) coupled to an HCT Ultra
ion trap (Bruker Daltonics, Bremen, Germany). The chip
contained a Zorbax 300SB-C18 (43 mm675 mm, with a 5 mm
particle size) column and a Zorbax 300SB-C18 (40 nL, 5 mm)
enrichment column. The solvent system consisted of 2% (v/v)
acetonitrile, 0.1% (v/v) formic acid in water (solvent A) and 2%
(v/v) water, 0.1% formic acid in acetonitrile (solvent B). The
sample was loaded into the enrichment column at a flow rate set to
3.75 mL/min with solvent A. Elution was performed at a flow rate
of 300 nL/min with a 8–40% linear gradient (solvent B) over
12 min and followed by a 70% stage (solvent B) over 5 min before
the reconditioning of the column at 92% of solvent A. The
complete system was fully controlled by ChemStation Rev.
B.01.03 (Agilent Technologies).
All the analyses were performed using an HCT+ ion trap
(Bruker Daltonics, Bremen Germany). The peptides were ionised
by positive electrospray and fragmented by CID. The trap was
externally calibrated with tunning mix for LC/MSD ion trap
G2431A (Agilent Technologies). The voltage applied to the
capillary cap was optimized to 21750 V. The MS scanning was
performedinthestandardenhancedresolutionmodeatascanrateof
8.100 m/z per second. The mass range was 250 to 2500 m/z. The
Ion Charge Control was 100000 and the maximum accumulation
time was 200 ms. A total of 4 scans were averaged to obtain a MS
spectrum and the rolling average was 2.
For tandem MS experiments, the system was operated with
automatic switching between MS and MS/MS modes. The 3 most
abundant peptides with an isolation width of 4 m/z, preferring
doubly charged ions (absolute threshold of 2000 and a relative of
5%) were selected on each MS spectrum for further isolation and
fragmentation. Ions were excluded after 2 spectra and released
after 1 min.
Smart Parameters Setting was used for selected precursor ions.
The MS/MS scanning was performed in the ultrascan resolution
mode at a scan rate of 26.000 m/z per second. The mass range
was 50 to 2800 m/z. The Ion Charge Control was 300000. A total
of 6 scans were averaged to obtain a MS/MS spectrum. The
values 30% and 200% give a start and end for fragmentation
relative to the fragmentation amplitude selected (1.5 V).
The complete system was fully controlled by EsquireControl 6.1
Build 90 (Bruker Daltonics) software. Mass data collected during
analysis were processed, converted into .mgf files using DataAna-
lysis 3.4 Build 179 (Bruker Daltonics) software. The standard
parameters were used.
The smoothing algorithm was Savitzky Golay with a smoothing
width of 0.2 m/z in 1 cycle. 250 compounds were selected with a
threshold of 60000. The algorithm ‘‘Accu Mass’’ was used.
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Mascot server (version MASCOT 2. 2.0, MatrixScience, UK).
Searches were performed with a mass tolerance of 200 ppm in MS
mode and 0.3 Da in MS/MS mode and with the following
parameters: trypsin specificity, one missed cleavage, cysteine
carbamidomethylation and methionine oxidation (and protein
amino-terminal acetylation) as variable modifications, trap frag-
mentation, without constraining protein molecular weight or
isoelectric point and without any taxonomic restriction.
To minimize false positive identifications, the results were
subjected to very stringent filtering criteria. For the identification
of a protein with two peptides or more, at least two unique
peptides had to a Mascot ion score above 20. In the case of single
peptide hits, the score of the unique peptide must be greater than
the 52. For the estimation of the false positive rate, a target-decoy
database search was performed [80]. In this approach, peptides
are matched against a database consisting of the native protein
sequences found in the database (target) and of the sequence-
reversed entries (decoy). The evaluations were performed using the
peptide validation software Scaffold (Proteome Software, Portland,
USA). This strategy was used to obtain a final catalogue of proteins
with an estimated false positive rate below 1%.
Drugs
Bromoenol Lactone (BEL), Thapsigargin (TG), Calmidazolium
(CMZ), Bromophenacyl bromide (BPB), 2-Aminoethyl diphenyl-
borinate (2-APB), N-6-aminohexyl-5-chloro-l-naphthalenesulfona-
mide (W7), Arachidonic acid (AA) and Rhodamine fluorophore,
5(6)-carboxytetramethyl rhodamine were purchased from Sigma
(St. Louis, MO, USA).
Statistical analysis
Group data are presented as mean6SD (as specified in the text
and figure legends). Student’s t test was used to determine the
significance of data (*), p,0.05.
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